WINTON GROUP Ltd Acquires New Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

WINTON GROUP Ltd purchased a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RAREGet Rating) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 5,678 shares of the biopharmaceutical company’s stock, valued at approximately $339,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. B. Metzler seel. Sohn & Co. AG bought a new stake in shares of Ultragenyx Pharmaceutical during the 1st quarter worth about $687,000. Seven Eight Capital LP bought a new stake in shares of Ultragenyx Pharmaceutical during the 1st quarter worth about $253,000. Verition Fund Management LLC bought a new stake in shares of Ultragenyx Pharmaceutical during the 1st quarter worth about $6,498,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth about $1,944,000. Finally, Harbor Capital Advisors Inc. raised its position in shares of Ultragenyx Pharmaceutical by 25.5% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 2,918 shares of the biopharmaceutical company’s stock worth $174,000 after buying an additional 592 shares in the last quarter. 88.27% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical Price Performance

Ultragenyx Pharmaceutical stock opened at $35.99 on Friday. The firm’s 50 day simple moving average is $39.78 and its 200-day simple moving average is $48.58. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $33.62 and a fifty-two week high of $88.22.

Analyst Upgrades and Downgrades

A number of analysts have commented on RARE shares. Credit Suisse Group dropped their price target on shares of Ultragenyx Pharmaceutical from $105.00 to $96.00 and set an “outperform” rating on the stock in a research report on Thursday, November 3rd. Cowen lowered their price objective on shares of Ultragenyx Pharmaceutical from $86.00 to $65.00 in a research note on Thursday, November 3rd. The Goldman Sachs Group lowered their price objective on shares of Ultragenyx Pharmaceutical from $74.00 to $55.00 and set a “neutral” rating on the stock in a research note on Friday, November 4th. Morgan Stanley lowered their price objective on shares of Ultragenyx Pharmaceutical from $109.00 to $100.00 and set an “overweight” rating on the stock in a research note on Thursday, November 3rd. Finally, Robert W. Baird raised shares of Ultragenyx Pharmaceutical from a “neutral” rating to an “outperform” rating and lowered their price objective for the stock from $63.00 to $50.00 in a research note on Thursday, November 3rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Ultragenyx Pharmaceutical currently has a consensus rating of “Moderate Buy” and an average price target of $92.86.

Insider Activity at Ultragenyx Pharmaceutical

In related news, CFO Mardi Dier sold 1,629 shares of the business’s stock in a transaction that occurred on Friday, October 14th. The shares were sold at an average price of $40.16, for a total transaction of $65,420.64. Following the transaction, the chief financial officer now directly owns 66,695 shares of the company’s stock, valued at $2,678,471.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 6.70% of the stock is currently owned by insiders.

Ultragenyx Pharmaceutical Company Profile

(Get Rating)

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

Recommended Stories

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RAREGet Rating).

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.